Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
Net Margin
Hubei Biocause Pharmaceutical Co Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
H
|
Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
|
19.3B CNY |
-2%
|
|
| ZA |
S
|
Sanlam Ltd
JSE:SLM
|
175.6B Zac |
13%
|
|
| ZA |
D
|
Discovery Ltd
JSE:DSY
|
133.7B Zac |
9%
|
|
| CN |
|
Ping An Insurance Group Co of China Ltd
SSE:601318
|
942.4B CNY |
14%
|
|
| CN |
|
China Life Insurance Co Ltd
SSE:601628
|
781.7B CNY |
28%
|
|
| ZA |
O
|
OUTsurance Group Ltd
JSE:OUT
|
106.4B Zac |
13%
|
|
| HK |
|
AIA Group Ltd
HKEX:1299
|
674.1B HKD |
23%
|
|
| US |
|
Aflac Inc
NYSE:AFL
|
59.5B USD |
29%
|
|
| IN |
|
Life Insurance Corporation Of India
NSE:LICI
|
5T INR |
5%
|
|
| ZA |
O
|
Old Mutual Ltd
JSE:OMU
|
57.4B Zac |
6%
|
|
| US |
|
MetLife Inc
NYSE:MET
|
56.8B USD |
6%
|
Hubei Biocause Pharmaceutical Co Ltd
Glance View
Hubei Biocause Pharmaceutical Co., Ltd began its journey in the health sector by positioning itself strategically in the pharmaceutical industry. With its headquarters set in the Hubei Province of China, this company has intricately woven itself into the fabric of modern healthcare. Primarily, it thrives by developing, manufacturing, and distributing a variety of pharmaceutical products including both traditional and modern-medicine drugs. The journey of Biocause is punctuated by its research-driven approach, which focuses on innovation and quality control across its production lines, ensuring it stays at the forefront of pharmaceutical advancements. Revenue generation for Hubei Biocause predominantly comes from the sale of medications and healthcare products, but the company's financial tapestry is more diversified. It has explored opportunities by extending its business horizon beyond pharmaceuticals, tapping into other ventures such as insurance services. This diversification has enabled Biocause to stabilize its financial structure and mitigate risk, leveraging its steady pharma income to branch into realms that complement its healthcare base. Alongside, their strategic partnerships and alliances further bolster their market position, allowing for a broadened geographical reach and a more substantial impact on the sectors they operate within. Thus, Hubei Biocause crafts a story not only of pharmaceutical excellence but of strategic breadth that spawns wider market opportunities.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Hubei Biocause Pharmaceutical Co Ltd's most recent financial statements, the company has Net Margin of -1.8%.
You don't have any saved screeners yet